Literature DB >> 32112774

Spectral-Domain Optical Coherence Tomography Analysis of Fibrotic Lesions in Neovascular Age-Related Macular Degeneration.

Eric H Souied1, Manar Addou-Regnard2, Avi Ohayon2, Oudy Semoun2, Giuseppe Querques2, Rocio Blanco-Garavito2, Roxane Bunod2, Camille Jung3, Anne Sikorav2, Alexandra Miere4.   

Abstract

PURPOSE: To describe the spectral-domain optical coherence tomography (OCT) features of fibrotic lesions associated with neovascular age-related macular degeneration (nAMD) and to outline the progression pathways from initial macular choroidal neovascular lesions (CNVs) to fibrosis.
METHODS: Patients with nAMD were retrospectively included when macular subretinal fibrosis was present. Fibrosis was categorized using spectral-domain OCT with respect to retinal pigment epithelium (RPE) in 836 spectral-domain OCT slices from 44 eyes of 39 patients. In addition, in 47 distinct eyes, 4181 spectral-domain OCT slices were retrospectively reviewed to longitudinally assess progression from the initial lesion to the final fibrosis.
RESULTS: Cross-sectional analysis classified fibrosis on spectral-domain OCT slices, as type A if located underneath the RPE, as type B if located above the RPE, and as type C if the remaining RPE was undistinguishable. The longitudinal analysis series revealed 3 progression pathways from the original CNV: 1) progression to type A, followed by RPE erosion and subretinal hyperreflective material, then type B and type C fibroglial lesion (FGL; 17/47 eyes); 2) progression to type B then type C FGL (17/47 eyes); and 3) persistence of type A with development of a flat, fibroatrophic lesion (13/47 eyes). Subretinal hyperreflective material, macular hemorrhage, or RPE tear occurred in 14 of 47, 13 of 47, and 10 of 47 eyes, respectively.
CONCLUSION: This spectral-domain OCT analysis identified various patterns of macular fibrosis in eyes with nAMD. Three pathways of progression to fibrosis were described including the well-established pathway of type 2 CNV progression to FGL and the progression of type 1 fibrovascular CNV to FGL or fibroatrophic lesion.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32112774     DOI: 10.1016/j.ajo.2020.02.016

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Inhibitory effect on subretinal fibrosis by anti-placental growth factor treatment in a laser-induced choroidal neovascularization model in mice.

Authors:  Yi Zhang; Ding-Ying Liao; Jian-Ming Wang; Li-Jun Wang; Xi-Ting Yang; Ai-Yi Zhou
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

2.  COVID-19 and macular edema: a necessarily blindness?

Authors:  Valentin Navel; Julien S Baker; Frédéric Dutheil
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-07-14       Impact factor: 3.117

3.  Differential Expression of Kinin Receptors in Human Wet and Dry Age-Related Macular Degeneration Retinae.

Authors:  Rahmeh Othman; Simon Berbari; Elvire Vaucher; Réjean Couture
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-24

4.  Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab.

Authors:  Davide Allegrini; Raffaele Raimondi; Giovanni Montesano; Alfredo Borgia; Tania Sorrentino; Panagiotis Tsoutsanis; Mario R Romano
Journal:  Clin Ophthalmol       Date:  2021-10-08

5.  Prechoroidal cleft thickness correlates with disease activity in neovascular age-related macular degeneration.

Authors:  Mariano Cozzi; Davide Monteduro; Salvatore Parrulli; Federica Ristoldo; Federico Corvi; Federico Zicarelli; Giovanni Staurenghi; Alessandro Invernizzi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-07       Impact factor: 3.117

6.  Optical coherence tomography features of the repair tissue following RPE tear and their correlation with visual outcomes.

Authors:  Francesco Romano; Salvatore Parrulli; Maurizio Battaglia Parodi; Marco Lupidi; Matteo Cereda; Giovanni Staurenghi; Alessandro Invernizzi
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.